Palivizumab

Type: Product
Name: Palivizumab
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Preventing RSV infections in our kids

As we head into fall and eventually winter, children may once again be exposed to many cold viruses.One of the worst is called Respiratory Syncytial Virus, or RSV for short.For most of us big people, and even for big kids, if we catch RSV we get nothing ... [Published Lake County News - Sep 10 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Free, Open Entrepreneur Office Hours Come to Baltimore

COLLEGE PARK, Md. , Sept. 9, 2014 /PRNewswire-USNewswire/ -- Innovators and entrepreneurs in Baltimore will have a new place to go for free, expert advice on launching their own companies or bringing their inventions to market every month starting on ... [Published Vision Monday - Sep 09 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 2 reports

UMD Program Approves 18 Technology Development Projects, Worth $4.7 Million, Teaming Maryland Faculty and Companies

COLLEGE PARK, Md., Sept. 9, 2014 /PRNewswire-USNewswire/ -- The Maryland Industrial Partnerships (MIPS) program, an initiative of the Maryland Technology Enterprise Institute (Mtech) in the A. James Clark School of Engineering at the University of Maryland, ... [Published BusinessWeek - Sep 09 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Market Update (NYSE:ABBV): AbbVie, Teva broke law in AndroGel "pay for delay" deal, U.S. says

[Reuters] – The U.S. Federal Trade Commission on Monday sued Drugmakers AbbVie Inc and Teva Pharmaceuticals Industries Ltd for allegedly illegally preventing generic versions of AndroGel, for men with low testosterone, …Read more on this.AbbVie Inc. (ABBV) ... [Published Jutia Group - Sep 09 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Therigy Debuts RSV Solution for TherigySTM

- Sep. 8, 2014 - MAITLAND, Fla. -- Therigy today announced the release of a new module, Respiratory Syncytial Virus (RSV), within its specialty therapy management application TherigySTM. Currently, Synagis® is the only FDA-approved drug commercially available ... [Published Prlog - Sep 08 2014]
First reported Sep 03 2014 - Updated Sep 04 2014 - 1 reports

NOVAVAX, INC. : Novavax to Present RSV Vaccine Clinical and Preclinical Results at ICAAC

GAITHERSBURG, Md., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today ... [Published 4 Traders - Sep 03 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Stock Update (NYSE:ABBV): AbbVie Cystic Fibrosis Scholarship Program Awards 40 Student Scholars With Annual Academic Awards

[PR Newswire] – NORTH CHICAGO, Ill., Aug. 18, 2014 /PRNewswire/ — AbbVie today announced the 40 outstanding students with cystic fibrosis (CF) who will each receive $2,500 to pursue their undergraduate or graduate school education during the 2014-2015 ... [Published Jutia Group - Aug 18 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Novavax Reports Second-Quarter 2014 Financial Results

GAITHERSBURG, Md., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today reported ... [Published Virtual Strategy Magazine - Aug 06 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Pediatricians clash with maker of drug for babies

Leading pediatrician's group says prescription Synagis should not be given to so many kids; drugmaker fires back ... [Published Latest Econwatch Headlines - CBS News - Jul 28 2014]
Entities: Drugs, Palivizumab
First reported Mar 20 2014 - Updated Mar 20 2014 - 1 reports

Annual Financial Report

Challenges to achieving commercial success of new productsImpactThe successful launch of a new pharmaceutical product involves substantial investment in sales and marketing activities, launch stocks and other items. The commercial success of our new medicines ... [Published TrustNet - Mar 20 2014]
Entities: Patent, biosimilar, Biology

Quotes

"Mtech is enthusiastic about the opportunity of bringing entrepreneur office hours to Baltimore ," said Peter Sandborn, Director of Mtech . "We have found this service to be an effective way of supporting our own entrepreneurial community by providing them with free access to proven experts, along with connections to the vast resources available to them in the State of Maryland . We look forward to getting to know the thriving entrepreneurship community in Baltimore ."
For information about the historical economic impact of the MIPS program, an independent study titled "An Analysis of the Impacts of MIPS Program Spending and the Commercialization of MIPS Funded Projects on the State of Maryland" by Richard Clinch, from the Jacob France Institute at the University of Baltimore, is available online
Slide Session Number 077: I-649. "Immunization of Pregnant Baboons with the RSV F Nanoparticle Vaccine Protects Infant Baboons Challenged with Respiratory Syncytial Virus in a Comparable Manner to Infants Prophylaxed with Palivizumab"
...We continue to make progress in our RSV and influenza vaccine development programs," said Stanley C Erck, President and CEO of Novavax. "The second half of 2014 will be the most productive period in the company's history. We plan to initiate 4 clinical studies before the end of 2014; RSV maternal immunization, pediatric and elderly, as well as a seasonal influenza clinical trial. We also plan to initiate a combination RSV/seasonal influenza clinical trial in early 2015. In addition, we plan to present pre-clinical and clinical data at several important medical meetings later this year."

More Content

All (12) | News (10) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Preventing RSV infections in our kids [Published Lake County News - Sep 10 2014]
Free, Open Entrepreneur Office Hours Come to Ba... [Published Vision Monday - Sep 09 2014]
UMD Program Approves 18 Technology Development ... [Published BusinessWeek - Sep 09 2014]
UMD Program Approves 18 Technology Development ... [Published Market Pulse Navigator - Sep 09 2014]
Market Update (NYSE:ABBV): AbbVie, Teva broke l... [Published Jutia Group - Sep 09 2014]
Therigy Debuts RSV Solution for TherigySTM [Published Prlog - Sep 08 2014]
NOVAVAX, INC. : Novavax to Present RSV Vaccine ... [Published 4 Traders - Sep 03 2014]
Stock Update (NYSE:ABBV): AbbVie Cystic Fibrosi... [Published Jutia Group - Aug 18 2014]
Novavax Reports Second-Quarter 2014 Financial R... [Published Virtual Strategy Magazine - Aug 06 2014]
Pediatricians clash with maker of drug for babies [Published Latest Econwatch Headlines - CBS News - Jul 28 2014]
Annual Financial Report [Published TrustNet - Mar 20 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 06 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Pediatricians clash with maker of drug for babies [Published Latest Econwatch Headlines - CBS News - Jul 28 2014]
Leading pediatrician's group says prescription Synagis should not be given to so many kids; drugmaker fires back ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 06 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.